A pivotal study published in JAMA reports that a single dose of a respiratory syncytial virus (RSV) vaccine substantially reduces severe illness and hospitalization among older adults across two consecutive seasons. Conducted by the IVY Network, this multicenter hospital research consortium's analysis underscores the durability of vaccine protection critical for vulnerable populations. These findings mark a significant advancement in respiratory disease prevention amid aging demographics.